Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pro-Dex, Inc. (NASDAQ: PDEX) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Pro-Dex operates in the surgical and medical instrument manufacturing industry, focusing on autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and its filings give detailed insight into how this business is structured and managed.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include discussions of net sales, gross profit, operating expenses, operating income, and the effects of product mix, repair programs, and costs such as tariffs. These filings also describe the importance of Pro-Dex’s largest customer, shipments of next generation orthopedic handpieces, and repair revenue for legacy products, all of which are central to understanding the company’s revenue profile.
Users can also examine current reports on Form 8-K, where Pro-Dex discloses material events such as earnings announcements, contract developments, executive and director compensation decisions, equity incentive awards, and the results of its annual meeting of shareholders. For example, recent 8-K filings detail restricted share grants under the company’s equity incentive plan, discretionary cash bonuses for executives, and shareholder voting outcomes on director elections, auditor ratification, and amendments to the equity incentive plan.
In addition, the proxy statement filed on Form DEF 14A provides information on corporate governance, board composition, executive compensation, and proposals submitted to shareholders. Together, these documents offer a comprehensive view of Pro-Dex’s financial reporting, governance practices, and key risks and opportunities.
On Stock Titan, Pro-Dex filings are updated from EDGAR and accompanied by AI-powered summaries that highlight the main points of lengthy 10-Ks, 10-Qs, and 8-Ks, helping readers quickly understand what has changed. The platform also makes it easier to navigate to filings related to executive and director compensation, equity plans, and other matters that can influence shareholders’ evaluation of PDEX.
Pro-Dex, Inc. (PDEX) director equity activity shows a small tax-related share forfeiture and a new restricted stock grant. On 11/20/2025, the reporting director forfeited 72 shares of common stock at a price of $30.83 to cover payroll taxes tied to the vesting of 200 restricted shares that were granted on 11/20/2024 under Pro-Dex's 2016 Equity Incentive Plan. On the same date, the director received a grant of 1,000 restricted common shares for no cash payment, also under the 2016 Equity Incentive Plan. These restricted shares vest in equal installments over five years, contingent on continued service with Pro-Dex. After these transactions, the director beneficially owned 15,447 common shares, held directly.
Pro-Dex, Inc. (PDEX) filed a Form 4 showing equity-related transactions by its Chief Financial Officer, Alisha Charlton. On 11/20/2025, 72 shares of common stock were forfeited at a price of $30.83 per share to cover payroll taxes tied to the vesting of 200 restricted shares granted on 11/20/2024 under the company’s 2016 Equity Incentive Plan. On the same date, Charlton received a grant of 1,000 restricted shares at a price of $0, also under the 2016 Equity Incentive Plan. Following these transactions, she beneficially owned 17,267 shares of Pro-Dex common stock directly. The newly granted restricted shares vest in equal installments over five years, as long as she continues her service with Pro-Dex over the vesting period.
Pro-Dex, Inc. (PDEX)1,000 shares of common stock at a price of $0.00, described as a grant of restricted shares under the company’s 2016 Equity Incentive Plan.
Following this grant, he beneficially owns 2,000 common shares directly and 270,846 common shares indirectly through Farnam Street Partners, L.P. This filing is a standard Form 4 disclosure of insider ownership and compensation in stock.
Pro-Dex, Inc. reported compensation actions and shareholder voting results. The Compensation Committee granted restricted common shares under its 2016 Equity Incentive Plan to non-employee directors and select employees, including 1,000 restricted shares to CFO Alisha K. Charlton, vesting in equal installments over five years, generally contingent on continued employment.
The Committee also approved a discretionary cash bonus to CEO Richard L. Van Kirk of $30,830, equal to the value of 1,000 shares based on the Nasdaq Capital Market closing price on November 20, 2025, to be paid in the next bi-weekly pay period. At the 2025 Annual Meeting, all director nominees were elected, shareholders ratified the company’s independent registered public accounting firm, approved on an advisory basis the compensation of Named Executive Officers and chose an annual advisory vote on that pay, and approved an additional proposal.
Pro-Dex, Inc. furnished a Form 8-K announcing it is issuing a press release covering financial performance for its first fiscal quarter ended September 30, 2025. The Item 2.02 information is expressly furnished, not filed for purposes of Section 18 of the Exchange Act. The press release is included as Exhibit 99.1.
Pro-Dex, Inc. reported stronger quarterly results. Net sales were $18.53 million, up 24% year over year, as orthopedic product shipments recovered and CMF drivers grew. Gross margin was 29% versus 35% a year ago, reflecting higher product costs, under‑absorption, and lower repair margins.
Operating income was $3.11 million. Other income rose to $3.11 million, including $3.30 million of unrealized gains on investments. Net income was $4.68 million, with diluted EPS of $1.40. Cash was $0.51 million and investments measured at fair value totaled $10.19 million. Working capital was $37.12 million. Notes payable were $13.28 million, and $2.16 million was drawn on the revolving loan.
Backlog was approximately $46.8 million, with $43.6 million scheduled for delivery during the remainder of fiscal 2026. Customer concentration remained high: one customer represented 78% of revenue and 84% of gross receivables. After quarter‑end, Pro-Dex received $8.9 million in cash from the Monogram sale and expects to record a $6.8 million realized gain in the next quarter; it also received contingent value rights tied to future milestones.
Pro‑Dex, Inc. discloses ownership, governance, compensation and equity-plan details in its definitive proxy. There are 3,280,004 shares outstanding and a group of directors, named executives and related parties hold 1,505,896 shares (45.9%). AO Partners I, L.P. holds 922,204 shares and those shares are pledged as collateral for a bank loan.
Board biographies highlight long tenure and industry experience in finance and medical devices. Executive pay descriptions show base salaries (CEO base noted at
Pro-Dex, Inc. filed a current report to share that it is releasing its financial results for the fourth fiscal quarter and fiscal year ended June 30, 2025. On September 4, 2025, the company issued a press release describing this performance, which is included as Exhibit 99.1. The company notes that the financial information in this item and the press release is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
Pro-Dex, Inc. filed its Form 10-K for fiscal 2025 describing operations in medical and scientific devices, including segment sales, balance sheet highlights, financing activity, and governance disclosures. Repairs revenue rose to $18,586 (up from $16,505), CMF sales totaled $9,943 (down ~4%), and thoracic sales increased by $1.3 million to $4.3 million. Operating income improved to $10,689 from $7,173. Investments carried net unrealized gains of $3.3 million at June 30, 2025 versus $1.8 million a year earlier. The company purchased a property for $6.5 million financed with a $5.2 million Property Loan. The revolving credit line was increased to $11.0 million and term loans carry maturities through 2029–2030 with a $3.1 million balloon due at maturity. Share repurchases totaled 130,148 shares at $3.5 million in fiscal 2025. The filing discloses customer concentration (major customer represented ~75% of sales) and notes cybersecurity risk management and standard risk-factor disclosures.
Pro-Dex, Inc. disclosed that its Compensation Committee approved discretionary cash bonuses for its two senior executives. On August 14, 2025, the committee granted a $50,000 bonus to Chief Financial Officer Alisha K. Charlton and a $70,000 bonus to Chief Executive Officer Richard L. Van Kirk. The company states that Mr. Van Kirk’s bonus was based on Pro-Dex’s sales growth and fiscal 2025 financial performance exceeding plan. Both bonuses will be paid in cash in the next bi-weekly pay period, with a pay date of August 21, 2025.